October 2016 DAWN Haematology Software E-Newsletter
In this issue:
Work Smarter - DAWN Version 7.9.59
Screen Improvements - Easier to Read
Using the DAWN Reminders, Visit and Patient Interventions screens is now even better with respacing and removal of less-used information.
History Tab on Patient Screen is now the Default Selection Unless a Preferred Setting has been Chosen
The Personal Settings button on the front screen opens a form where you can set personal preferences including Initial Patient Tab Sheet. This setting determines whether the Graph, History or Personal tab is selected by default when you open the Patient screen.
In previous versions of DAWN, if you didn’t have a preference defined for Initial Patient Tab Sheet, the Patient screen opened with either the Graph or the Personal tab selected. In 7.9.59, if you have no Initial Patient Tab Sheet preference defined, the History tab is the initial default. This makes more sense as History is the most frequently used tab. If you then select another tab, the new tab remains selected when you move between patient records for the rest of your logged in session.
To adjust your Personal Setting, click on Settings on the front screen and edit your InitialPatientTabSheet.
Phases Tab opens for you on Treatment Plan Screen
By default, when you open the Treatment Plan screen, the first tab (“Test Limits”) is selected. If you select a different tab, such as Phases, this new tab remains selected for each Treatment Plan screen you open during your logged-in session. However, once you log out and close your browser this selection is forgotten so the next time you go into DAWN and open a Treatment Plan screen, it reverts to having the Test Limits tab selected.
The most used tab is Phases not Test Limits and in version 7.9.59 you can configure the system to always select the Phases tab (for everyone every time) whenever you open a Treatment Plan screen by changing the system setting, NonAC_TreatmentPlan_DefaultToPhasesTab to 0.
Interventions Tab opens for you when Moving Between Patient screens
The patient screen opens initially with the Interventions tab selected. If you then select another tab, the new tab remains selected when you move between patient records for the rest of your logged in session.
This is still the default behaviour in version 7.9.59, however you can now configure your system to always reselect the Interventions tab when you move from one patient to the next. This behaviour is controlled by amending the system setting, NonAC_PatientForm_AlwaysSelectInterventionsTab.
For more information about upgrading your DAWN CH system to the latest version, which is included as part of your annual maintenance contract, contact the 4S DAWN team at email@example.com or +44 (0) 15395 63091.
Important Support and Troubleshooting information for your DAWN CH system
Don't forget that there is a wealth of resources on the 4S DAWN website to support you in using the DAWN CH system.
The User & Safety Manual and Troubleshooting guides are designed to help you get the most out of your DAWN CH system and can be accessed via the support page of the 4S DAWN website.
The guides are regularly updated and are available to download as pdfs so that you can save them to your desk top for easy access at a future date.
How to record visit notes in DAWN including historical cards
If you use spreadsheets along with stored pdf's for clinic notes and want to have easy access to all of these notes at multidisciplinary team meetings etc, you can do this in DAWN CH so that they are all stored in a central, easily accessible location.
The Documents tab allows upload of the older documents which might be a scanned paper card with hand-written notes or a Word document or spreadsheet. Just click on the new button to name and browse for the file.
To record ongoing clinic notes, you may select to use the Procedures tab and the type (clinic note, Wednesday clinic, Nurse visit, ...) can be set under System menu, LookupTables, Procedure. On the Procedures tab, click on the new button to record the type and notes. The notes may be pasted in or free text. Coded comments do not apply for these notes.
Expand your capabilities with DAWN
There are a number of add-on modules available for DAWN CH designed to help customers expand their capabilities and improve productivity and efficiency. The following modules are available for DAWN CH systems:
- Interfaces - test results, demographics, admission and discharge, GP summary, medications and many more
For more information about any of the additional modules, contact the 4S DAWN team today - firstname.lastname@example.org.
As the range of application areas covered by 4S DAWN Clinical Software increases, there has been lots of interest in using DAWN within other departments and many customers now have a number of DAWN systems installed within their hospital/Trust.
The DAWN software now covers the following areas:
If you or any of your colleagues would be interested in learning more about any of the areas above, contact the 4S DAWN team today at email@example.com to discuss your requirements and see a demonstration of the software in action.
Did you know...
- Alcohol Liaison
- Anaemia Management
- Heart Failure
- Multiple Sclerosis
NICE rejects Imbruvica for non-Hodgkin’s lymphoma
NICE has once again rejected Johnson & Johnson's Imbruvica (ibrutinib) for use on the NHS in England and Wales, this time for the treatment of patients with a rare form of lymphoma.
In draft guidance the UK watchdog cited a lack of cost-effectiveness evidence submitted for patients where chemo-immunotherapy is considered unsuitable, and is therefore not minded to recommend the drug.
More Patient Education, Communication May Improve Myeloproliferative Neoplasm Care
More patient education and patient-physician communication among those with myeloproliferative neoplasms (MPNs) may improve care and satisfaction, according to a study published in Cancer.
Researchers led by Ruben Mesa, MD, of the Mayo Clinic Cancer Center in Scottsdale, Arizona, conducted a survey that included 813 patients who had MPNs, polycythemia vera (PV), or essential thrombocythemia (ET), as well as 457 hematologist/oncologist respondents who treated patients diagnosed with these conditions.
AbbVie and Roche's leukaemia drug venetoclax nears EU market
AbbVie and Roche are on track for approval of their chronic lymphocytic leukaemia (CLL) drug venetoclax on both sides of the Atlantic after the Committee for Medicinal Products for Human Use gave a conditional green light for the drug.
The first-in-class BCL-2 inhibitor was first launched in the US earlier this year as Venclexta for the treatment of adult CLL patients with the 17p deletion or TP53 mutation, which is seen in around 10% of all newly-diagnosed patients with this form of cancer and is a difficult-to-treat form of the disease, typically associated with poor prognosis.
Follow us on our LinkedIn Page!
4S DAWN Clinical Software has a new LinkedIn company page where you can keep up to date with all of the latest news and developments. Follow us and join our LinkedIn community: CLICK HERE